Publications by authors named "D G Stover"
Purpose: While MEK inhibitors demonstrated activity in metastatic triple negative breast cancer (mTNBC) preclinical studies, preclinical, and clinical studies implicate rapid development of resistance limiting clinical benefit. The purpose of this study was to determine response rate for Trametinib alone and in combination with Uprosertib in patients with mTNBC previously treated with chemotherapy.
Methods: This was an open-label, two-part, phase II, single-arm, multicenter study.
Therapy-induced molecular adaptation of triple-negative breast cancer is crucial for immunotherapy response and resistance. We analyze tumor biopsies from three different time points in the randomized neoadjuvant GeparNuevo trial (NCT02685059), evaluating the combination of durvalumab with chemotherapy, for longitudinal alterations of gene expression. Durvalumab induces an activation of immune and stromal gene expression as well as a reduction of proliferation-related gene expression.
View Article and Find Full Text PDFBackground: Dietary patterns promoting chronic inflammation, including the empirical dietary inflammatory pattern (EDIP), have been associated with certain cancers. Investigating whether this dietary pattern is associated with breast cancer-where the role of inflammation is less well-defined-could provide valuable insights and potentially improve strategies for preventing this cancer.
Methods: We prospectively followed 76,386 women from Nurses' Health Study (NHS, 1984-2018) and 92,886 women from Nurses' Health Study II (NHSII, 1991-2019).
Article Synopsis
- Chemotherapy often leads to severe gastrointestinal issues in patients, with existing treatments failing to provide adequate relief.
- Recent findings suggest that the gut microbiome influences the severity of these symptoms, prompting research into identifying pre-chemotherapy microbiome markers.
- In a study of 59 breast cancer patients, lower microbiome diversity and specific microbial abundance predicted worse gastrointestinal symptoms during chemotherapy, indicating potential for personalized preventative strategies based on microbiome health before treatment.
Background: Breast cancer, one of the most common forms of cancer, is associated with the highest cancer-related mortality among women worldwide. In comparison to other types of breast cancer, patients diagnosed with the triple-negative breast cancer (TNBC) subtype have the worst outcome because current therapies do not produce long-lasting responses. Hence, innovative therapies that produce persisting responses are a critical need.
View Article and Find Full Text PDF